February 28, 2019
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Notice concerning Nominations for the Board of Directors /the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board

SymBio Pharmaceuticals Limited (“the Company”) today announced that proposals for the election of six(6) directors, one (3) Audit & Supervisory Board member, and one (1) substitute member for the Audit &Supervisory Board will be submitted at the 14th Ordinary General Meeting of Shareholders scheduled forMarch 28, 2019 (the “14th Shareholders Meeting”). The Company’s Board of Directors today approved thesubmission of the proposals to the shareholders at the 14th Shareholders Meeting.
1.

Nomination of Candidates for the Board of Directors(1) Nomination of Candidates for the Board of Directors (Re-nomination)
Mr. Fuminori Yoshida, Representative Director, President & CEO
Mr. Kazuo Asakawa, Representative Director, Executive Vice President & CCO
Mr. Shigetoshi Matsumoto, Representative Director (Outside)(2) Nomination of Candidates for the Board of Directors (Newly nominated)
Mr. Kenji Murata, Corporate Officer & CFO
Profile of the Candidate
Date of Birth July 19, 1968
April, 1991

Sumitomo Life Insurance Company.

October, 2004

Strategic Sourcing Manager of Novartis Pharma K.K.

July, 2007

Head of Oncology Planning & Control of Novartis Pharma K.K.

CareerJanuary, 2014

Country CFO of Novartis Animal Health K.K.

Summary

January, 2015

Country CFO of Elanco Japan (acquisition of Eli Lilly)

December, 2016
March, 2018

Head of Finance and Accounting of SymBio Pharmaceuticals
LimitedCorporate Officer, CFO of SymBio Pharmaceuticals Limited

Mr. Dr. Bruce David ChesonProfile of the Candidate
Date of Birth April 06, 1946
CareerJuly, 1971

Internship of Internal Medicine, University of Virginia Hospital

1SummaryJuly, 1973

July, 1974

July, 1977

October, 1984

June, 2001

Senior Assistant Resident of Internal Medicine, University ofVirginia Hospital
Clinical and Research Fellow of Hematology, New England
Medical Center Hospital
Assistant Professor of Medicine, Hematology/Oncology ofUniversity of Utah School, University of Utah Hospital
Senior Investigator and Head of Medicine Section, NationalCancer Institute, Cancer Therapy Evaluation Program
Scientific Advisory Board, Lymphoma Research Foundation(current)Deputy Chief, Hematology-Oncology, Head of Hematology,

July, 2002

Georgetown University Hospital, Lombardi Comprehensive
Cancer CenterMarch, 2013

Hematology-Oncology Fellowship Program Director GUHAugust, 2016

External board of director, Morphosys (current)

December, 2018

Frank M. Ewing Foundation Chair in Hematology-Oncology(current)

Mr. Rockford Douglas Norby
Profile of the Candidate
Date of Birth June 28, 1935
September, 1979
February,1985
CareerDecember, 1996

Summary
September, 1999

2.

Senior Vice President and Chief Financial Officer of Syntex
Corporation
President and Chief Operating Officer of Lucasfilm, Ltd.
Board of director, Executive Vice President of LSI LogicCorporation
Director and Chair of the Audit Committee, Lead Independent
Director of Alexion

March, 2010

Chairman of the Board of MagnaChip Semiconductor

November, 2017

Board of Director of Krystal Biotech, Inc. (current)

Nomination of Candidate for the Audit & Supervisory Board(1) Nomination of Candidates for the Audit & Supervisory Board (Re-nomination)
Mr. Kiyoshi Watanabe, the Audit & Supervisory Board (Outside)
Mr. Kesao Endo, the Audit & Supervisory Board (Outside)(2) Nomination of Candidates for the Audit & Supervisory Board (Outside) (Newly nominated)
Mr. Eiji Ebinuma

2

Profile of the Candidate
Date of Birth July 3,1957
April, 1980

April, 2002
CareerSummary3.

April, 2003

The Industrial Bank of Japan, Ltd (Currently Mizuho BankLtd.)
Deputy General Manager of Personnel Dept., Head of Planningteam , Mizuho Bank, Ltd.
Head of President Office and Planning dept., Olympic Group
Corporation

December, 2008

Attoney-At-Law, Toranomon Sougoh Law Firm

January, 2013

Attoney-At-Law, Partner, Tanabe&Partners

June, 2014

Outside Director, MIRAIT Holdings Corporation (current)

June, 2016

Outside Director, Rakuten Bank, Ltd.(current)

Nomination of Candidates as a Substitute Member of the Audit & Supervisory Board(1) Nomination of Candidates as a Substitute Member of the Audit & Supervisory Board (Outside)(Re-nomination)
Mr. Mr. Takashi Watanabe as a Substitute Member of the Audit & Supervisory Board (Outside)

4.

Members of the Board of Directors and the Audit & Supervisory Board who will resign(1) Board of Directors
Dr. George Morstyn, Director (Outside)
Dr. Milton Grannatt, Director (Outside)
Mr. Robin Campbell, Director (Outside)(2) Audit & Supervisory Board MemberMr. Saneaki Ichijo (Outside)[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

3